Zalicus
Inc. a biopharmaceutical business enterprise that is actually discovers and
develops novel therapies for affected individuals suffering from pain and
immuno-inflammatory health conditions, introduced that it has efficiently
completed a Phase 1 single ascending dose (SAD) study along with Z944, its
novel, oral, T-type calcium channel blocker. The study achievement implies that
Z944 was usually well-tolerated and a most tolerated dose ended up being
achieved. Z944 will improve into a Phase 1 multiple ascending dose (MAD) study
within the third quarter of 2012. Taking on Z944 successfully completes the MAD
survey; Z944 could get into Phase 2 clinical progress to begin with quarter of
2013.
"Based
on their individual mechanism of action, T-type calcium channel blockers an
example would be Z944 have the potential to supply relief of pain along with
other symptoms in affected individuals affected by acute and chronic
inflammatory pain, such as post-operative pain, fibromyalgia and inflammatory
bowel syndrome that significant disorder areas wherein novel agents along with
improved tolerability, performance, and permanent safety profiles are necessary,"
stated Mark H.N. Corrigan, MD, President and CEO of Zalicus.
No comments:
Post a Comment